Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

As good as it gets? The problem of HIV persistence despite antiretroviral drugs.

Sigal A, Baltimore D.

Cell Host Microbe. 2012 Aug 16;12(2):132-8. doi: 10.1016/j.chom.2012.07.005.

2.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
3.

Targeting viral reservoirs: ability of antiretroviral therapy to stop viral replication.

Maldarelli F.

Curr Opin HIV AIDS. 2011 Jan;6(1):49-56. doi: 10.1097/COH.0b013e32834134ea. Review.

PMID:
21228755
4.

What do we need to do to cure HIV infection.

Siliciano RF.

Top HIV Med. 2010 Aug-Sep;18(3):104-8. Review.

5.

Reservoirs of HIV replication after successful combined antiretroviral treatment.

Belmonte L, Baré P, de Bracco MM, Ruibal-Ares BH.

Curr Med Chem. 2003 Feb;10(4):303-12. Review.

PMID:
12570703
6.
7.

Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.

Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, Perelson AS, Wolinsky SM.

N Engl J Med. 1999 May 27;340(21):1614-22.

8.

HIV-1 dynamics in vivo: implications for therapy.

Simon V, Ho DD.

Nat Rev Microbiol. 2003 Dec;1(3):181-90. Review.

PMID:
15035022
9.

The development of immune-modulating compounds to disrupt HIV latency.

Remoli AL, Marsili G, Battistini A, Sgarbanti M.

Cytokine Growth Factor Rev. 2012 Aug-Oct;23(4-5):159-72. doi: 10.1016/j.cytogfr.2012.05.003. Epub 2012 Jul 4. Review.

PMID:
22766356
10.

Epigenetic regulation of HIV-1 persistence and evolving strategies for virus eradication.

Dhamija N, Rawat P, Mitra D.

Subcell Biochem. 2013;61:479-505. doi: 10.1007/978-94-007-4525-4_21. Review.

PMID:
23150264
11.

The challenge of finding a cure for HIV infection.

Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ.

Science. 2009 Mar 6;323(5919):1304-7. doi: 10.1126/science.1165706. Review.

PMID:
19265012
12.

Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy.

Sharkey ME, Teo I, Greenough T, Sharova N, Luzuriaga K, Sullivan JL, Bucy RP, Kostrikis LG, Haase A, Veryard C, Davaro RE, Cheeseman SH, Daly JS, Bova C, Ellison RT 3rd, Mady B, Lai KK, Moyle G, Nelson M, Gazzard B, Shaunak S, Stevenson M.

Nat Med. 2000 Jan;6(1):76-81.

PMID:
10613828
13.

Curing HIV: Pharmacologic approaches to target HIV-1 latency.

Choudhary SK, Margolis DM.

Annu Rev Pharmacol Toxicol. 2011;51:397-418. doi: 10.1146/annurev-pharmtox-010510-100237. Review.

14.

[Viral dynamics in the course of HIV-1 infection: pathogenetic features and new therapeutic prospects].

Marcello A, Giacca M.

Pathologica. 2000 Aug;92(4):291-3. Italian. No abstract available.

PMID:
11029891
15.

Reservoirs of HIV-1 in vivo: implications for antiretroviral therapy.

Saksena NK, Potter SJ.

AIDS Rev. 2003 Jan-Mar;5(1):3-18. Review.

PMID:
12875103
16.

Antiviral drugs that target cellular proteins may play major roles in combating HIV resistance.

Provencher VM, Coccaro E, Lacasse JJ, Schang LM.

Curr Pharm Des. 2004;10(32):4081-101. Review.

PMID:
15579090
17.

Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection.

Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M, Chadwick K, Margolick J, Quinn TC, Kuo YH, Brookmeyer R, Zeiger MA, Barditch-Crovo P, Siliciano RF.

Nature. 1997 May 8;387(6629):183-8.

PMID:
9144289
18.

Latency: the hidden HIV-1 challenge.

Marcello A.

Retrovirology. 2006 Jan 16;3:7. Review.

19.
20.

Two long terminal repeat circles and persistent HIV-1 replication.

Sharkey ME, Stevenson M.

Curr Opin Infect Dis. 2001 Feb;14(1):5-11. Review.

PMID:
11979108

Supplemental Content

Support Center